Serum Institute On “Inaccurate” Comparison Amid Row Over Vaccine Prices

The vaccine manufacturer flagged the “inaccurate comparison done between the global prices of the vaccine with India”

Serum Institute On 'Inaccurate' Comparison Amid Row Over Vaccine Prices

Mumbai/New Delhi:

The Serum Institute on Saturday responded to criticism over its open-market pricing of the Covishield coronavirus vaccine – to be sold at Rs 600 per dose to private hospitals, Rs 400 to states and Rs 150 to the centre from May 1, when vaccination opens to everyone over the age of 18.

The manufacturer flagged “inaccurate comparison between the global prices of the vaccine with India”, and stressed that Covishield – one of two vaccines currently used in the country – remained “the most affordable COVID-19 vaccine available in the market today”. 

“Only a limited portion of SII’s volume will be sold to private hospitals at Rs 600 per dose. The price of the vaccine is still lower than a lot of other medical treatment and essentials required to treat COVID-19 and other life-threatening diseases,” the SII said in its statement.

“The initial prices (of Covishield) were kept very low globally as it was based on advance funding given by those countries for at-risk vaccine manufacturing. The initial supply price for all government immunisation programmes, including India, has been the lowest,” the company added.

The company also said that while the current situation is “dire; the virus is constantly mutating while the public remains at risk… we have to ensure sustainability as we must be able to invest in scaling up and expanding our capacity to fight the pandemic and save lives.

The clarification comes after a report in the Indian Express newspaper that said that at Rs 600 a dose, people in India could pay the most, of any other country, for Covishield at private hospitals.

Those getting their shots at state-run hospitals could end up paying the full Rs 400 per dose if states decide they cannot absorb the costs of procuring fresh doses directly from the makers.

The report said the Rs 400 cost was higher even than that paid by governments in countries like the United States and United Kingdom to source directly from vaccine co-developers AstraZeneca.


SII produces AstraZeneca-Oxford University’s Covid vaccine for India under the name ‘Covishield’ (File) 

The report also prompted the centre to issue a clarification of its own; the centre reminded people that vaccines procured by it and given to states would continue to be free, and those provided to private hospitals would be available at the subsidised rate of Rs 250 per dose.

However, the centre’s statement said nothing on the higher prices of vaccines that states and private hospitals may source directly from the manufacturers, under new rules that allow them to sell up to 50 per cent of their output to states and private hospitals

On Wednesday the centre had confirmed the prices at which Covishield will be sold from May 1. SII had said prices would be cheaper than other nations, where it can cost up to Rs 1,500 per shot.

The centre has also confirmed Rs 3,000 crore in advance funds for SII. This was after CEO Adar Poonawalla told NDTV existing production capacities were “very stressed, to put it frankly”.

The ramping up, Mr Poonawalla later said, would start immediately and that, by the end of May, he expected there would be 15 to 20 per cent more doses of Covishield in the market.

Mr Poonawalla told NDTV SII would be able to supply over 100 million doses per month after July.

Leave a Comment

All the data shown above will be stored by on At any point of time, you can contact us and select the data you wish to anonymise or delete so it cannot be linked to your email address any longer. When your data is anonymised or deleted, you will receive an email confirmation. We also use cookies and/or similar technologies to analyse customer behaviour, administer the website, track users' movements, and to collect information about users. This is done in order to personalise and enhance your experience with us. Click here to read our Cookie Policy.